Glaucoma News and Research

Latest Glaucoma News and Research

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme.

10 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.

31 Jan 2014

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Using a novel high-throughput screening process, scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma.

24 Jan 2014

Clues of "silent thief of sight”: Glaucoma

Glaucoma is sometimes called the "silent thief of sight" because it slowly damages the eyes and can cause irreparable harm before there is any vision loss. But this disease is stealthy in more ways than one.

22 Jan 2014

Probability of blindness from glaucoma drops by half, say researchers

A comparative long-range study by Mayo Clinic ophthalmology researchers shows that the probability of blindness from glaucoma 20 years after diagnosis has dropped by half in the last generation. The findings appear online in the "in press" section of the journal Ophthalmology.

22 Jan 2014

Study: Probability of blindness due to glaucoma has decreased by nearly half

The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.

21 Jan 2014

Sleeping position influences glaucoma visual loss

Researchers from South Korea suggest that patients with glaucoma should avoid sleeping on one side, after showing that it may be associated with greater visual field loss in the lower-positioned eye.

20 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Ocular Therapeutix announced today it has received approval from the Food and Drug Administration to commercialize the ReSure Sealant in the United States, with an indication for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

10 Jan 2014

Akorn acquires NDA and all rights to Betimol from Santen

Akorn, Inc., a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping Betimol in the first quarter of 2014.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Residual structures in brain play key role in restoring vision in stroke patients

Scientists know that vision restoration training (VRT) can help patients who have lost part of their vision due to glaucoma, optic nerve damage, or stroke regain some of their lost visual functions, but they do not understand what factors determine how much visual recovery is achieved.

6 Jan 2014

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Scientists develop new potential cure for rare eye disease

University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.

22 Dec 2013

New optical device puts the power to detect retinal disease in the palm of a hand

A new optical device puts the power to detect eye disease in the palm of a hand. The tool-about the size of a hand-held video camera-scans a patient's entire retina in seconds and could aid primary care physicians in the early detection of a host of retinal diseases including diabetic retinopathy, glaucoma and macular degeneration.

22 Dec 2013

Spaceflights cause cellular-level damage and may lead to long-term vision problems

Those who travel to space are rewarded with a beautiful sight - planet Earth. But the effects of space travel on the human sense of sight aren't so beautiful. More than 30 percent of astronauts who returned from two-week space shuttle missions and 60 percent who spent six months aboard the International Space Station were diagnosed with eye problems. Two recent investigations examined mechanisms that may explain eye changes in spaceflight, help find ways to minimize this health risk to astronauts and eventually prevent and treat eye diseases on Earth.

13 Dec 2013

EyeTechCare's new EyeOP1 device now available in six more French health care facilities

EyeTechCare SA, which develops non-invasive therapeutic medical devices for the ophthalmology market based on the use of ultrasound, today announces that six more health care facilities in France now have the new EyeOP1 device.

11 Dec 2013

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

10 Dec 2013

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.

9 Dec 2013

Glaucoma News and Research

Latest Glaucoma News and Research

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida announces financial results for second quarter 2014

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Clues of "silent thief of sight”: Glaucoma

Probability of blindness from glaucoma drops by half, say researchers

Study: Probability of blindness due to glaucoma has decreased by nearly half

Sleeping position influences glaucoma visual loss

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Akorn acquires NDA and all rights to Betimol from Santen

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Residual structures in brain play key role in restoring vision in stroke patients

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Scientists develop new potential cure for rare eye disease

New optical device puts the power to detect retinal disease in the palm of a hand

Spaceflights cause cellular-level damage and may lead to long-term vision problems

EyeTechCare's new EyeOP1 device now available in six more French health care facilities

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in